While many drug companies now see development as key to boosting productivity, Novartis is investing heavily in its own discovery capacity. A new research head has been hiring hot shots out of biotech firms and academia, assembling new technologies to complement classical skills. Novartis seems to be striving to be mostly self-dependent. Will the bet pay off?
By Deborah Erickson
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
Kevin Parker leads Cartography Biosciences in developing precision therapies for underserved cancer types, targeting proteins exclusive to tumor cells.
